-
Je něco špatně v tomto záznamu ?
Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity
O. Uher, V. Caisova, P. Hansen, J. Kopecky, J. Chmelar, Z. Zhuang, J. Zenka, K. Pacak,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, Research Support, N.I.H., Intramural, přehledy
Grantová podpora
ZIA HD008735-18
Intramural NIH HHS - United States
- MeSH
- adaptivní imunita MeSH
- fagocytóza účinky léků imunologie MeSH
- imunitní systém imunologie metabolismus MeSH
- imunomodulace MeSH
- imunoterapie * metody MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- ligandy MeSH
- nádorové mikroprostředí účinky léků genetika imunologie MeSH
- nádory etiologie metabolismus patologie terapie MeSH
- přirozená imunita MeSH
- protinádorové látky imunologicky aktivní farmakologie terapeutické užití MeSH
- toll-like receptory metabolismus MeSH
- výsledek terapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Research Support, N.I.H., Intramural MeSH
There is no doubt that immunotherapy lies in the spotlight of current cancer research and clinical trials. However, there are still limitations in the treatment response in certain types of tumors largely due to the presence of the complex network of immunomodulatory and immunosuppressive pathways. These limitations are not likely to be overcome by current immunotherapeutic options, which often target isolated steps in immune pathways preferentially involved in adaptive immunity. Recently, we have developed an innovative anti-cancer immunotherapeutic strategy that initially elicits a strong innate immune response with subsequent activation of adaptive immunity in mouse models. Robust primary innate immune response against tumor cells is induced by toll-like receptor ligands and anti-CD40 agonistic antibodies combined with the phagocytosis-stimulating ligand mannan, anchored to a tumor cell membrane by biocompatible anchor for membrane. This immunotherapeutic approach results in a dramatic therapeutic response in large established murine subcutaneous tumors including melanoma, sarcoma, pancreatic adenocarcinoma, and pheochromocytoma. Additionally, eradication of metastases and/or long-lasting resistance to subsequent re-challenge with tumor cells was also accomplished. Current and future advantages of this immunotherapeutic approach and its possible combinations with other available therapies are discussed in this review.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005684
- 003
- CZ-PrNML
- 005
- 20200525141421.0
- 007
- ta
- 008
- 200511s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1053/j.seminoncol.2019.10.004 $2 doi
- 035 __
- $a (PubMed)31739997
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Uher, Ondrej $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, MD 20814, USA; Department of Medical Biology, Faculty of Science, University of South Bohemia, Ceske Budejovice 37005, Czech Republic.
- 245 10
- $a Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity / $c O. Uher, V. Caisova, P. Hansen, J. Kopecky, J. Chmelar, Z. Zhuang, J. Zenka, K. Pacak,
- 520 9_
- $a There is no doubt that immunotherapy lies in the spotlight of current cancer research and clinical trials. However, there are still limitations in the treatment response in certain types of tumors largely due to the presence of the complex network of immunomodulatory and immunosuppressive pathways. These limitations are not likely to be overcome by current immunotherapeutic options, which often target isolated steps in immune pathways preferentially involved in adaptive immunity. Recently, we have developed an innovative anti-cancer immunotherapeutic strategy that initially elicits a strong innate immune response with subsequent activation of adaptive immunity in mouse models. Robust primary innate immune response against tumor cells is induced by toll-like receptor ligands and anti-CD40 agonistic antibodies combined with the phagocytosis-stimulating ligand mannan, anchored to a tumor cell membrane by biocompatible anchor for membrane. This immunotherapeutic approach results in a dramatic therapeutic response in large established murine subcutaneous tumors including melanoma, sarcoma, pancreatic adenocarcinoma, and pheochromocytoma. Additionally, eradication of metastases and/or long-lasting resistance to subsequent re-challenge with tumor cells was also accomplished. Current and future advantages of this immunotherapeutic approach and its possible combinations with other available therapies are discussed in this review.
- 650 _2
- $a adaptivní imunita $7 D056704
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky imunologicky aktivní $x farmakologie $x terapeutické užití $7 D000074322
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunitní systém $x imunologie $x metabolismus $7 D007107
- 650 _2
- $a přirozená imunita $7 D007113
- 650 _2
- $a imunomodulace $7 D056747
- 650 12
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a nádory $x etiologie $x metabolismus $x patologie $x terapie $7 D009369
- 650 _2
- $a fagocytóza $x účinky léků $x imunologie $7 D010587
- 650 _2
- $a toll-like receptory $x metabolismus $7 D051193
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nádorové mikroprostředí $x účinky léků $x genetika $x imunologie $7 D059016
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Intramural $7 D052060
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Caisova, Veronika $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, MD 20814, USA.
- 700 1_
- $a Hansen, Per $u Immunoaction LLC, Charlotte, Vermont, VT 05445, USA.
- 700 1_
- $a Kopecky, Jan $u Department of Medical Biology, Faculty of Science, University of South Bohemia, Ceske Budejovice 37005, Czech Republic.
- 700 1_
- $a Chmelar, Jindrich $u Department of Medical Biology, Faculty of Science, University of South Bohemia, Ceske Budejovice 37005, Czech Republic.
- 700 1_
- $a Zhuang, Zhengping $u Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, MD 20814, USA.
- 700 1_
- $a Zenka, Jan $u Department of Medical Biology, Faculty of Science, University of South Bohemia, Ceske Budejovice 37005, Czech Republic.
- 700 1_
- $a Pacak, Karel $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, MD 20814, USA. Electronic address: karel@mail.nih.gov.
- 773 0_
- $w MED00004330 $t Seminars in oncology $x 1532-8708 $g Roč. 46, č. 4-5 (2019), s. 385-392
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31739997 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200525141420 $b ABA008
- 999 __
- $a ok $b bmc $g 1524542 $s 1095740
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 46 $c 4-5 $d 385-392 $e 20191106 $i 1532-8708 $m Seminars in oncology $n Semin Oncol $x MED00004330
- GRA __
- $a ZIA HD008735-18 $p Intramural NIH HHS $2 United States
- LZP __
- $a Pubmed-20200511
